Travere Therapeutics Corporate Overview June 2021 © 2021 Travere Therapeutics, Inc. Forward-Looking Statements 2 This presentation contains forward-looking statements, including statements about our prospects, products, growth projections, competitive position, potential regulatory filings and agency actions, and the anticipated development, timing, data readouts and therapeutic scope of programs in our clinical pipeline. These forward- looking statements may be accompanied by such words as "anticipate," "b ...

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2021 Earnings Conference Call May 6, 2021 4:30 PM ET Company Participants Chris Cline - Vice President, Investor Relations & Corporate Communications Eric Dube - Chief Executive Officer Noah Rosenberg - Chief Medical Officer Peter Heerma - Chief Commercial Officer Laura Clague - Chief Financial Officer Bill Rote - Senior Vice President, Research and Development Conference Call Participants Joseph Schwartz - SVB Leerink Greg Harrison - Bank of America Maury Raycrof ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________ FORM 10-Q _________________________________ ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact name o ...

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2020 Earnings Conference Call March 1, 2021 4:30 PM ET Company Participants Chris Cline - Vice President, Investor Relations and Corporate Communications Eric Dube - Chief Executive Officer Noah Rosenberg - Chief Medical Officer Peter Heerma - Chief Commercial Officer Laura Clague - Chief Financial Officer Bill Rote - Senior Vice President, Research and Development Conference Call Participants Greg Harrison - Bank of America Carter Gould - Barclays Joseph Schwartz ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 27-4842691 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 3611 Valley Centre Drive, Suite 300 San Diego, CA 92130 (Addres ...

Retrophin, Inc. (RTRX) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Chris Cline – Vice President, Investor Relations and Corporate Communications Eric Dube – Chief Executive Officer Noah Rosenberg – Chief Medical Officer Peter Heerma – Chief Commercial Officer Laura Clague – Chief Financial Officer Bill Rote – Senior Vice President, Research and Development Conference Call Participants Scott Puckhaber – Bank of America Michelle Gilson – Canaccord Genuity Laura Chico – We ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________ FORM 10-Q _________________________________ ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-36257 RETROPHIN, INC. (Exact name of regis ...

1 Corporate Overview Delivering Life-Changing Therapies to People Living with Rare Diseases August 2020 Forward-Looking Statements This presentation contains forward-looking statements, including statements about our prospects, products, growth projections, competitive position, potential regulatory filings and agency actions, and the anticipated development, timing, data readouts and therapeutic scope of programs in our clinical pipeline. These forwardlooking statements may be accompanied by such words as ...

Retrophin, Inc. (RTRX) Q2 2020 Earnings Conference Call July 30, 2020 4:30 PM ET Company Participants Chris Cline - Vice President, Investor Relations and Corporate Communications Eric Dube - Chief Executive Officer Noah Rosenberg - Chief Medical Officer Peter Heerma - Chief Commercial Officer Laura Clague - Chief Financial Officer Bill Rote - Senior Vice President, Research and Development Conference Call Participants Joseph Schwartz - SVB Leerink Michelle Gilson - Canaccord Genuity Tom Lugo - William Blai ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________ FORM 10-Q _________________________________ For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36257 RETROPHIN, INC. (Exact name of registrant ...